Navigation Links
SanBio Announces The Completion Of Enrollment Of Its Clinical Trial Of Cell Therapy For Chronic Stroke Deficits

MOUNTAIN VIEW, Calif., Sept. 4, 2013 /PRNewswire/ -- SanBio Inc. today announced the successful completion of enrollment of patients in its Phase 1/2 clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, in patients suffering from chronic deficits resulting from previous stroke injuries. A total of 18 patients have been successfully administered SB623. The trial is being conducted at Stanford University and the University of Pittsburgh. No safety concerns have been attributed to the cell therapy product. For details regarding this clinical trial, please refer to

SB623 is derived from bone marrow and has shown safety and efficacy in rodent models of chronic stroke.  "Complete enrollment of this clinical trial is a major step in the development of SB623 for stroke patients. Planning for the next phase of testing is already underway." said Keita Mori, SanBio CEO.

SB623 is being delivered to the damaged region of the brains of patients who have suffered an ischemic stroke.  Product safety is the primary focus of the study but various measurements of efficacy are also being tested.

"Stroke is the major cause of disability in the United States. Regenerative medicine offers hope to those with otherwise permanent functional limitations. This trial represents an important advance in bringing restorative therapeutics for neurologic disorders into the clinical arena. Three measures of efficacy (NIHSS, ESS, Fugl-Meyer) all show a trend toward improvement.  We are looking forward to the next clinical trial," said Dr. Gary K. Steinberg, M.D., Ph.D., Bernard and Ronni Lacroute-William Randolph Hearst Professor of Neurosurgery and the Neurosciences, Director, Stanford Institute for Neuro-Innovation and Translational Neurosciences, Chairman, Department of Neurosurgery, Stanford University School of Medicine.

Dr. Steinberg will be presenting preliminary results from this clinical trial at the International Stroke Conference February 12-14 in San Diego, California.

"Completion of this study is an important milestone in development of cell therapy treatment for chronic stroke. The demonstration of safety and feasibility is encouraging and we look forward to further trials using these cells," said Dr. Lawrence R. Wechsler, M.D., Henry B. Higman Professor and Chair, Department of Neurology, University of Pittsburgh Medical School

"The SanBio trial was completed smoothly and will help to guide important research into stroke repair and regenerative medicine strategies. It is hoped that the next study can begin soon and advance patient care," said Dr. Douglas Kondziolka, MD, MSc ,FRCSC, FACS,Professor of Neurosurgery, Vice-Chair, Clinical Research (Neurosurgery), Professor of Radiation Oncology, Director, Center for Advanced Radiosurgery, NYU Langone Medical Center.

About SB623: SB623 is a proprietary allogeneic cell therapy product consisting of cells derived from bone marrow.  SB623 is administered adjacent to the area damaged by stroke and functions by producing proteins that aid the regenerative process.

About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of new regenerative cell therapy products.

For more information:

SOURCE SanBio Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury
2. Ryan & Maniskas, LLP Announces Class Action Lawsuit Against NuVasive, Inc.
3. Hamilton Regional Laboratory Medicine Program Announces Decision to Acquire COPANs WASPLab, the Next Generation Full Laboratory Automation and Digital Bacteriology System
4. IVD Technology Magazine Announces the IVD Business Strategy Conference in San Diego
5. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
6. Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger
7. Encision Announces Death of Chief Executive Officer Fred F. Perner
8. Sanomedics Announces Completion of Prime Time Medical Acquisition
9. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
10. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
11. Neurotrope, Inc., Announces Reverse Merger and Completion of $21.9 Million Private Offering
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
Breaking Medicine News(10 mins):